In places without healthcare infrastructure, patient follow-up is infrequent so the initial consult and having the correct information for a healthcare provider to make a decision is critical. Further, a majority of illnesses and diseases have treatment algorithms that require not only a PCR result, but potentially a measurement of the host response and general health of the patient. This is why multiomics and multimodal testing is a key driver in the platform solution that Fluxergy is developing.
Our goal is to provide as much diagnostic health information as possible per test that can be leveraged during the initial consult to expedite diagnosis and treatment. By decentralizing data collection via deployable platforms in community-based settings, we can aggregate more data at the population level to drive clinical decision making.
Fluxergy was created 10 years ago by Ryan Revilla and Tej Patel developing a working prototype analyzer and microfluidic cartridge system for HIV-1 testing out of their garage and apartment. Since Fluxergy has started, we have grown from a team of three in a garage to 100+ collaborating employees at Fluxergy’s technology and manufacturing campus totaling 70,000 sq. ft, cGMP-compliant and ISO/MDSAP certified and European offices. Fluxergy is expanding its technology to anywhere that lab testing can be better served including animal health, food safety, and forensics industries. The platform technology we’ve developed enables us to understand our world and our health in ways which were never possible before.